Switzerland
· Delayed Price · Currency is CHF Molecular Partners AG Statistics
Total Valuation
Molecular Partners AG has a market cap or net worth of CHF 167.30 million. The enterprise value is 11.22 million.
| Market Cap | 167.30M |
| Enterprise Value | 11.22M |
Important Dates
The next estimated earnings date is Friday, October 25, 2024.
| Earnings Date | Oct 25, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Molecular Partners AG has 33.19 million shares outstanding. The number of shares has increased by 13.89% in one year.
| Shares Outstanding | 33.19M |
| Shares Change (YoY) | +13.89% |
| Shares Change (QoQ) | +4.75% |
| Owned by Insiders (%) | 4.92% |
| Owned by Institutions (%) | 13.97% |
| Float | 17.33M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 21.11 |
| PB Ratio | 1.08 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -0.19 |
| EV / Sales | 1.43 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -0.18 |
Financial Position
The company has a current ratio of 14.58, with a Debt / Equity ratio of 1.96.
| Current Ratio | 14.58 |
| Quick Ratio | 14.30 |
| Debt / Equity | 1.96 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.05 |
| Interest Coverage | -2,136.93 |
Financial Efficiency
Return on equity (ROE) is -31.88% and return on invested capital (ROIC) is -21.00%.
| Return on Equity (ROE) | -31.88% |
| Return on Assets (ROA) | -19.31% |
| Return on Capital (ROIC) | -21.00% |
| Revenue Per Employee | 48,531 |
| Profits Per Employee | -355,716 |
| Employee Count | 162 |
| Asset Turnover | 0.04 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -0.97% in the last 52 weeks. The beta is 0.61, so Molecular Partners AG's price volatility has been lower than the market average.
| Beta (5Y) | 0.61 |
| 52-Week Price Change | -0.97% |
| 50-Day Moving Average | 5.71 |
| 200-Day Moving Average | 4.38 |
| Relative Strength Index (RSI) | 37.82 |
| Average Volume (20 Days) | 12,020 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Molecular Partners AG had revenue of CHF 7.86 million and -57.63 million in losses. Loss per share was -1.75.
| Revenue | 7.86M |
| Gross Profit | -42.85M |
| Operating Income | -61.97M |
| Pretax Income | -57.63M |
| Net Income | -57.63M |
| EBITDA | -61.05M |
| EBIT | -61.97M |
| Loss Per Share | -1.75 |
Balance Sheet
The company has 159.13 million in cash and 3.05 million in debt, giving a net cash position of 156.08 million or 4.70 per share.
| Cash & Cash Equivalents | 159.13M |
| Total Debt | 3.05M |
| Net Cash | 156.08M |
| Net Cash Per Share | 4.70 |
| Equity (Book Value) | 155.57M |
| Book Value Per Share | 4.69 |
| Working Capital | 154.24M |
Cash Flow
In the last 12 months, operating cash flow was -61.95 million and capital expenditures -702,000, giving a free cash flow of -62.65 million.
| Operating Cash Flow | -61.95M |
| Capital Expenditures | -702,000 |
| Free Cash Flow | -62.65M |
| FCF Per Share | -1.89 |
Margins
| Gross Margin | n/a |
| Operating Margin | -788.23% |
| Pretax Margin | -732.97% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | -796.91% |
Dividends & Yields
Molecular Partners AG does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -13.89% |
| Shareholder Yield | -13.89% |
| Earnings Yield | -34.71% |
| FCF Yield | -37.45% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |